Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20085874 | 0.91 | TRPA1 (0.40) | ADORA2AHPGDTRPA1XDHMAPT | |
| SCHEMBL20085870 | 0.87 | ADORA2A (0.50) | ADORA2ATRPA1NOS1MAPT | |
| SCHEMBL20089044 | 0.86 | ADORA2A (0.41) | ADORA2AHPGDTRPA1 | |
| SCHEMBL20088871 | 0.86 | TRPA1 (0.40) | ADORA2AHPGDTRPA1ADORA3 | |
| SCHEMBL20085872 | 0.83 | ADORA2A (0.43) | ADORA2ATRPA1NOS1MAPT | |
| SCHEMBL20085877 | 0.83 | ADORA2A (0.47) | ADORA2ATRPA1NOS1MAPT | |
| SCHEMBL20085843 | 0.82 | ADORA2A (0.46) | ADORA2ATRPA1NOS1MAPT | |
| SCHEMBL20085860 | 0.82 | ADORA2A (0.44) | ADORA2ATRPA1NOS1MAPT | |
| SCHEMBL20088872 | 0.79 | TRPA1 (0.51) | ADORA2AHPGDTRPA1XDHADORA3 | |
| SCHEMBL20085869 | 0.78 | TRPA1 (0.43) | ADORA2ATRPA1XDHMAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | ADORA2A 135/4885HPGD 814/4885TRPA1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.